Ligand Pharmaceuticals Inc. (LGND)
Ligand Pharmaceuticals Inc. (LGND) is a biopharmaceutical company that focuses on the development and acquisition of technology platforms and proprietary products for the advancement of innovative medicines. The company partners with other pharmaceutical firms to develop and commercialize drug candidates, leveraging its expertise in biology, chemistry, and process development to streamline drug discovery and development.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| July 1, 2010 | $0.08 | 2010-07-02 | 2010-06-28 |
| April 19, 2007 | $2.50 | 2007-04-03 | 2007-04-05 |
Dividends Summary
- Ligand Pharmaceuticals Inc. has issued 2 dividend payments over the past 3 years
- The most recent dividend was paid 5560 days ago, on July 1, 2010
- The highest dividend payed out to investors during this period was $2.5 per share
- The average dividend paid during this period was $1.29 per share.
Company News
The global topical drugs Contract Development and Manufacturing Organization (CDMO) market is projected to grow from $46.32 billion in 2024 to $136.71 billion by 2034, with a CAGR of 11.43%. Key growth drivers include increasing demand for non-invasive therapies, advancements in drug delivery technologies, and expanding pharmaceutical outsourcing.
Palvella Therapeutics, a clinical-stage biopharmaceutical company, has appointed Matthew E. Korenberg as its new Chief Financial Officer. Korenberg brings over 27 years of senior executive experience in the biotech and healthcare investment banking industries.
Ligand Pharmaceuticals (LGND) has reached a new 52-week high of $103.295, reflecting the company's strong financial performance and growth potential. The company has made several strategic moves, including acquiring APEIRON Biologics and expanding its credit facility, which have contributed to its positive market performance.
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.
